Cryo-Save Group N.V. (CRYO) 0.6500 $CRYO
American CryoStem Announces Breakthroughs in the Expansion and Lineage-Specific Differentiations of Adipose-Derived Stem Cells
GlobeNewswire - Thu Apr 24, 8:14AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading biotechnology developer and licensor of patented adipose tissue-based adult stem cell technologies, today announced that its ACS Laboratory division has completed its quarterly laboratory R&D program ahead of schedule, yielding new intellectual property and positive results for expanding and differentiating adipose-derived stem cells (ADSCs). Breakthroughs in American CryoStem's proprietary cell culture medium (ACSelerate) and culturing methodology have enabled the Company to accelerate the robust cellular expansion and rapid differentiation of ADSCs to adipocytes (fat cells), chondrocytes (cartilage-producing cells) and osteocytes (bone-producing cells). Working with its patented media technologies, the Company has been able to accelerate early adipocyte formation to within 24 to 72 hours; to produce chondrocyte filaments contracting into early cartilaginous tissue within 48 to 72 hours; and to form heavily mineralized, trabecular bone tissue within 11 days -- processes that typically require several weeks to complete.
American CryoStem and Rutgers University File Joint Patent on Adipose-Derived Stem Cell Platform Technology
GlobeNewswire - Thu Apr 10, 7:00AM CDT
Combined Technologies Create Basis for Joint Development of
American CryoStem Selected as "Incubator Company of the Year" by New Jersey Business Incubation Network (NJBIN)
GlobeNewswire - Wed Apr 09, 8:22AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading biotechnology developer and global licensor of patented adipose tissue-based adult stem cell technologies, today announced that the Company has been selected as an "Incubator Company of the Year" by the New Jersey Incubation Network ("NJBIN"
. The award will be presented at NJBIN's upcoming Second Annual Business Incubation Awards to be held on April 25, 2014 at the EcoComplex - Rutgers University's Alternative Energy Innovation and Environmental Research & Extension Center in Bordentown Township, New Jersey.
Rent-A-Center, Inc. Announces Fourth Quarter and Year End 2013 Earnings Call and Webcast
GlobeNewswire - Wed Jan 15, 11:16AM CST
Rent-A-Center, Inc. (Nasdaq:RCII) today announced it will host a conference call on Tuesday, January 28, at 10:45 a.m. ET to discuss fourth-quarter results slated for release following the market's close on January 27. Live audio of the conference call will be available on the company's investor relations website at http://investor.rentacenter.com. A replay will be available beginning January 28 at 1:45 p.m. ET.
American CryoStem Posts Letter to Shareholders
GlobeNewswire - Mon Jan 06, 12:45PM CST
John Arnone, Chairman and CEO of American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today issued a formal update in the form of a Letter to Shareholders posted to the Company's web site at www.americancryosystem.com.
Best's Rating Notification - Cincinnati Life Insurance Company
Rating Division - AMBest - Thu Dec 19, 1:14PM CST
A.M. Best Company has made the following rating update:
Life Stem Genetics Inc partners with American CryoStem for patient's adipose tissue sample storage
M2 - Mon Nov 25, 4:26AM CST
Healthcare company Life Stem Genetics Inc (OTC BB:LIFS) reported on Friday the launch of a strategic collaborative agreement for the long term storage of their patient's adipose tissue sample.
Life Stem Genetics Announces Collaborative Agreement with American CryoStem
Business Wire - Fri Nov 22, 7:30AM CST
Life Stem Genetics, Inc. (OTCBB:LIFS) announced today a strategic collaborative agreement with American CryoStem Corporation, (OTCBB:CRYO). CRYO is a leading developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries.
American CryoStem and Protein Genomics Form Autogenesis Corporation to Support Development of Unique Stem Cell-Based Wound Products
GlobeNewswire - Thu Nov 14, 7:30AM CST
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced the formation of Autogenesis Corporation ("Autogenesis" as part of its collaborative agreement to develop wound healing products and other cellular therapies with privately-held Protein Genomics (PGen).
American Cryostem Granted Interlinked an Exclusive Interview During Recent FSXinterlinked Investment Conference
PRWeb - Tue Aug 27, 3:38AM CDT
At the recent FSXinterlinked Investment Conference, held at the Ritz Carloton in Fort Lauderdale, Florida, American Cryostem's Chairman and CEO, John Arnone, granted an exclusive interview for the FSXinterlinked channel on InterlinkedTV.
American CryoStem Granted IRB Approval for Adipose Derived Stem Cell Processing Protocols
GlobeNewswire - Wed Jul 10, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that its protocols for the processing of Stromal Vascular Fraction (SVF) and culturing of mesenchymal stem cells from autologous adipose tissue have been approved by the Institutional Review Board (IRB) of the International Cell Surgical Society (ICSS).
American CryoStem to Present at OneMedForumNY 2013
GlobeNewswire - Wed Jun 26, 8:35AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at OneMedForumNY 2013 to be held at the Metropolitan Club in New York City, June 26-27, 2013.
Under-valued Stem Cell Innovator Targets Growing Markets
ACCESSWIRE - Wed Jun 26, 8:00AM CDT
American CryoStem (CRYO) Targets Growing End Markets
American CryoStem Welcomes Noted Cryopreservation Expert, Dr. Dayong Gao, to Medical & Scientific Advisory Board
GlobeNewswire - Mon Jun 24, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that Dayong Gao, Ph.D. has been appointed to the Company's Medical and Scientific Advisory Board.
Fat Cells Lending to New Treatments in Brain Cancer
ACCESSWIRE - Thu Jun 13, 12:30PM CDT
Regenerative medicines hold incredible potential for new, more potent therapeutics to arrive in the future for a broad spectrum of diseases and conditions. As the industry in general is growing, more possibilities are emerging seemingly on a daily basis as research uncovers new ways to use stem cells to potentially combat deadly diseases like cancer where many patients have little to no hope with today's standards of care.
American CryoStem to Present at National Investment Banking Association's 126th Investment Conference
GlobeNewswire - Tue Jun 04, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at the National Investment Banking Association's (NIBA) 126 Investment Conference to be held in New York City, June 17-19, 2013.
Investment Ideas in the Expanding Wound Care Market
ACCESSWIRE-TNW - Fri May 17, 10:55AM CDT
Investing in Wound Care's Real Growth Drivers
American CryoStem Partners with Rutgers for Novel Wound Care Product
ACCESSWIRE-TNW - Tue May 14, 11:01AM CDT
Regenerative medicine is constantly discovering new inroads to potential therapies utilizing adult stem cells for a variety of life threatening or debilitating conditions and diseases. Progress has accelerated in the past few years, fueled in part by President Obama's 2009 Executive Order 13505 that "removed barriers" in responsible research which has opened doors to examination of new ways of thinking. It has also aided in the emergence of research in the area of adipose (fat)-based stem cell therapy, which could prove to be a major breakthrough in regenerative medicine. Not only has early research at Johns Hopkins suggested the possibility of superior efficacy with Adipose-Derived Stem Cells, or ADSCs, in the treatment of glioblastoma (a severe form of brain cancer), but ADSCs are easily harvested, meaning that they could become a standard as the most reliable and abundant source of stem cells for research, cultures and therapeutic processes.
American CryoStem to Collaborate With Rutgers University on Adipose-Derived Stem Cell Research
GlobeNewswire - Tue May 14, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based and cellular technologies for the Regenerative and Personalized Medicine industries, today announced that it has entered into Material Transfer Agreements with three leading research scientists at Rutgers, The State University of New Jersey, distinguished as one of the world's premier universities for stem cell research and training.
The Beauty of American CryoStem Now and in the Future
ACCESSWIRE-TNW - Thu May 09, 1:12PM CDT
"What can I do with my unwanted body fat?" That is a question that is posed by American CryoStem (OTCQB: CRYO) on the home page of its website. There are plenty of finite resources in the world, but let's face it, body fat certainly isn't one of them. A little due diligence reveals the company's answer to that question, but a more discerning examination uncovers the true growth potential of American CryoStem from an immediate, mid-term and long-term perspective.
American CryoStem Announces Breakthroughs in the Expansion and Lineage-Specific Differentiations of Adipose-Derived Stem Cells
GlobeNewswire - Thu Apr 24, 8:14AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading biotechnology developer and licensor of patented adipose tissue-based adult stem cell technologies, today announced that its ACS Laboratory division has completed its quarterly laboratory R&D program ahead of schedule, yielding new intellectual property and positive results for expanding and differentiating adipose-derived stem cells (ADSCs). Breakthroughs in American CryoStem's proprietary cell culture medium (ACSelerate) and culturing methodology have enabled the Company to accelerate the robust cellular expansion and rapid differentiation of ADSCs to adipocytes (fat cells), chondrocytes (cartilage-producing cells) and osteocytes (bone-producing cells). Working with its patented media technologies, the Company has been able to accelerate early adipocyte formation to within 24 to 72 hours; to produce chondrocyte filaments contracting into early cartilaginous tissue within 48 to 72 hours; and to form heavily mineralized, trabecular bone tissue within 11 days -- processes that typically require several weeks to complete.
American CryoStem and Rutgers University File Joint Patent on Adipose-Derived Stem Cell Platform Technology
GlobeNewswire - Thu Apr 10, 7:00AM CDT
Combined Technologies Create Basis for Joint Development of
American CryoStem Selected as "Incubator Company of the Year" by New Jersey Business Incubation Network (NJBIN)
GlobeNewswire - Wed Apr 09, 8:22AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading biotechnology developer and global licensor of patented adipose tissue-based adult stem cell technologies, today announced that the Company has been selected as an "Incubator Company of the Year" by the New Jersey Incubation Network ("NJBIN"
. The award will be presented at NJBIN's upcoming Second Annual Business Incubation Awards to be held on April 25, 2014 at the EcoComplex - Rutgers University's Alternative Energy Innovation and Environmental Research & Extension Center in Bordentown Township, New Jersey. Rent-A-Center, Inc. Announces Fourth Quarter and Year End 2013 Earnings Call and Webcast
GlobeNewswire - Wed Jan 15, 11:16AM CST
Rent-A-Center, Inc. (Nasdaq:RCII) today announced it will host a conference call on Tuesday, January 28, at 10:45 a.m. ET to discuss fourth-quarter results slated for release following the market's close on January 27. Live audio of the conference call will be available on the company's investor relations website at http://investor.rentacenter.com. A replay will be available beginning January 28 at 1:45 p.m. ET.
American CryoStem Posts Letter to Shareholders
GlobeNewswire - Mon Jan 06, 12:45PM CST
John Arnone, Chairman and CEO of American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today issued a formal update in the form of a Letter to Shareholders posted to the Company's web site at www.americancryosystem.com.
Best's Rating Notification - Cincinnati Life Insurance Company
Rating Division - AMBest - Thu Dec 19, 1:14PM CST
A.M. Best Company has made the following rating update:
Life Stem Genetics Inc partners with American CryoStem for patient's adipose tissue sample storage
M2 - Mon Nov 25, 4:26AM CST
Healthcare company Life Stem Genetics Inc (OTC BB:LIFS) reported on Friday the launch of a strategic collaborative agreement for the long term storage of their patient's adipose tissue sample.
Life Stem Genetics Announces Collaborative Agreement with American CryoStem
Business Wire - Fri Nov 22, 7:30AM CST
Life Stem Genetics, Inc. (OTCBB:LIFS) announced today a strategic collaborative agreement with American CryoStem Corporation, (OTCBB:CRYO). CRYO is a leading developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries.
American CryoStem and Protein Genomics Form Autogenesis Corporation to Support Development of Unique Stem Cell-Based Wound Products
GlobeNewswire - Thu Nov 14, 7:30AM CST
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced the formation of Autogenesis Corporation ("Autogenesis"
as part of its collaborative agreement to develop wound healing products and other cellular therapies with privately-held Protein Genomics (PGen). American Cryostem Granted Interlinked an Exclusive Interview During Recent FSXinterlinked Investment Conference
PRWeb - Tue Aug 27, 3:38AM CDT
At the recent FSXinterlinked Investment Conference, held at the Ritz Carloton in Fort Lauderdale, Florida, American Cryostem's Chairman and CEO, John Arnone, granted an exclusive interview for the FSXinterlinked channel on InterlinkedTV.
American CryoStem Granted IRB Approval for Adipose Derived Stem Cell Processing Protocols
GlobeNewswire - Wed Jul 10, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that its protocols for the processing of Stromal Vascular Fraction (SVF) and culturing of mesenchymal stem cells from autologous adipose tissue have been approved by the Institutional Review Board (IRB) of the International Cell Surgical Society (ICSS).
American CryoStem to Present at OneMedForumNY 2013
GlobeNewswire - Wed Jun 26, 8:35AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at OneMedForumNY 2013 to be held at the Metropolitan Club in New York City, June 26-27, 2013.
Under-valued Stem Cell Innovator Targets Growing Markets
ACCESSWIRE - Wed Jun 26, 8:00AM CDT
American CryoStem (CRYO) Targets Growing End Markets
American CryoStem Welcomes Noted Cryopreservation Expert, Dr. Dayong Gao, to Medical & Scientific Advisory Board
GlobeNewswire - Mon Jun 24, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that Dayong Gao, Ph.D. has been appointed to the Company's Medical and Scientific Advisory Board.
Fat Cells Lending to New Treatments in Brain Cancer
ACCESSWIRE - Thu Jun 13, 12:30PM CDT
Regenerative medicines hold incredible potential for new, more potent therapeutics to arrive in the future for a broad spectrum of diseases and conditions. As the industry in general is growing, more possibilities are emerging seemingly on a daily basis as research uncovers new ways to use stem cells to potentially combat deadly diseases like cancer where many patients have little to no hope with today's standards of care.
American CryoStem to Present at National Investment Banking Association's 126th Investment Conference
GlobeNewswire - Tue Jun 04, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at the National Investment Banking Association's (NIBA) 126 Investment Conference to be held in New York City, June 17-19, 2013.
Investment Ideas in the Expanding Wound Care Market
ACCESSWIRE-TNW - Fri May 17, 10:55AM CDT
Investing in Wound Care's Real Growth Drivers
American CryoStem Partners with Rutgers for Novel Wound Care Product
ACCESSWIRE-TNW - Tue May 14, 11:01AM CDT
Regenerative medicine is constantly discovering new inroads to potential therapies utilizing adult stem cells for a variety of life threatening or debilitating conditions and diseases. Progress has accelerated in the past few years, fueled in part by President Obama's 2009 Executive Order 13505 that "removed barriers" in responsible research which has opened doors to examination of new ways of thinking. It has also aided in the emergence of research in the area of adipose (fat)-based stem cell therapy, which could prove to be a major breakthrough in regenerative medicine. Not only has early research at Johns Hopkins suggested the possibility of superior efficacy with Adipose-Derived Stem Cells, or ADSCs, in the treatment of glioblastoma (a severe form of brain cancer), but ADSCs are easily harvested, meaning that they could become a standard as the most reliable and abundant source of stem cells for research, cultures and therapeutic processes.
American CryoStem to Collaborate With Rutgers University on Adipose-Derived Stem Cell Research
GlobeNewswire - Tue May 14, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based and cellular technologies for the Regenerative and Personalized Medicine industries, today announced that it has entered into Material Transfer Agreements with three leading research scientists at Rutgers, The State University of New Jersey, distinguished as one of the world's premier universities for stem cell research and training.
The Beauty of American CryoStem Now and in the Future
ACCESSWIRE-TNW - Thu May 09, 1:12PM CDT
"What can I do with my unwanted body fat?" That is a question that is posed by American CryoStem (OTCQB: CRYO) on the home page of its website. There are plenty of finite resources in the world, but let's face it, body fat certainly isn't one of them. A little due diligence reveals the company's answer to that question, but a more discerning examination uncovers the true growth potential of American CryoStem from an immediate, mid-term and long-term perspective.
